Egypt Atherosclerosis Drugs Market Analysis

The Egypt Atherosclerosis Drugs Market size stood at around xx Bn in 2023 and is projected to reach US $xx Bn by 2033, exhibiting a CAGR of xx% during the forecast period.

The Egypt Atherosclerosis Drugs Market Analysis Executive Summary

Atherosclerosis is a type of arteriosclerosis that results from the formation of plaque on the walls of your arteries. A disease associated with atherosclerosis is the main cause of death in the United States of America. Atherosclerosis occurs gradually when cholesterol, fat, blood cells and other substances in the blood form a plaque. This build-up will gradually make your arteries constrict. This results in decreased supply of oxygen containing blood to the tissues of essential organs in the body. Atherosclerosis was found to be present in frequencies ranging from 17% for subjects who were ≤20 years of age to 85% for those who were ≥50 years of age. Drugs used to treat atherosclerosis include statins like rosuvastatin, marketed as Crestor, which is useful in cholesterol management and maintaining healthy blood vessels. 

Major classes of drugs include statins that lower cholesterol, and other drugs such as PCSK9 inhibitors, antiplatelet agents, ACE inhibitors, ARBs, fibrates, and niacin. Some of the current trends are the rising concept of pharmacogenomics, escalating use of combination therapies, and advanced drug delivery systems. Pharmaceutical companies are key players in this market, with entrants being newer bio technology firms. Various challenges are there such as regulatory issues, high expenses, and the issue of handling side effects. Nonetheless, it is predicted that the market will rise because of the continual rise in cardiovascular diseases and advancements in treatment.    

Egypt Atherosclerosis Drugs Market Dynamics

Market Growth Drivers

Several factors have contributed towards growth of atherosclerosis drugs market these include, rising incidences of cardiovascular diseases and population globally is aging. Increased consumption of unhealthy foods and tobacco products accelerates atherosclerosis cases and creates demand for health services. Increased customer knowledge and focus on cardiovascular wellness and rising government concern and better expenditure on health, particularly in the developing world, are also driving the market further. The focus on primary care, as well as the development of health care facilities in developing countries, also helped contribute to the increased demand for atherosclerosis medications.

Opportunity

The atherosclerosis drugs market is expected to exhibit strong growth in future, especially in Asia-Pacific, Latin America, and Middle East & Africa due to increasing cases of CVD, improving healthcare expenditure, and growth infrastructure. New drug classes are biologics, mAbs, targeted therapies, and combination treatments addressing unique disease processes to enhance treatment efficacy. It also increase the focus on preventive measures and early interventions which means more options to provide screening, improve patient counselling and to integrate the life-style changes with pharmacologic therapy. Also, the application of digital health technologies in atherosclerosis care including telemonitoring and individualized treatment plans should improve the condition’s management. 

Market Restraints

Expensive treatment and the availability of cheaper generics limit access to therapies via affordability especially in the low-income countries. Lack of diagnostic rates and awareness about atherosclerosis result in low diagnosis and timely treatment. Additional market challenges include regulatory barriers, high incidences of products recalls, and poor healthcare systems especially in the developing world. Economic fluctuations can also affect the adoption of specialized treatments and procedures. Overcoming these challenges requires multi-stakeholder collaboration involving healthcare professionals, policy makers and pharmaceutical industries for the expansion of access to good treatment.

Competitive Landscape Atherosclerosis Drugs Market in Egypt

Key Players

• Pfizer Inc. 
• AstraZeneca PLC 
• Merck & Co., Inc. 
• Amgen Inc. 
• Regeneron Pharmaceuticals, Inc. 
• Novartis AG 
• Sanofi S.A. 
• Bristol-Myers Squibb Company

Recent Developments

June 2024, Zydus receives USFDA tentative approval for Azilsartan Medoxomil and Chlorthalidone Tablets.

March 2019, USFDA approved a new generic of Diovan (valsartan). Valsartan is an angiotensin II receptor blocker (ARB) that treats high blood pressure and heart failure.

Mergers and Acquisitions

February 2023, Medtech giant has made plans to acquire Cardiovascular Systems, a Minnesota-based maker of atherectomy devices. Abbott offers $890M for artery-cleaning device maker Cardiovascular Systems.

January 2020, Novartis successfully completes acquisition of The Medicines Company, adding a potentially first-in-class, investigational cholesterol-lowering therapy inclisiran.

Healthcare Policies and Regulatory Landscape for Atherosclerosis Drugs Market in Egypt

Policy changes and Reimbursement scenario

The matter of fact is government healthcare expenditure which is promoting the growth of the market by financing better medical facilities and structure for cardiovascular diseases. But, more stringent regulations while helpful in protecting the rights of patients sometimes hampers the availability of newer forms of cure. Promotion of awareness is important in ensuring people acquire knowledge regarding atherosclerosis thus the increased tendency of people to seek medications. Some countries offer good reimbursement policies and are situated in the developed world, while others, situated in the developing world, suffer from constraints. Value-based care and other evolving reimbursement models are emerging as cost-effectiveness becomes a priority, leading to changes in reimbursement practices. Concerns about the accessibility of generics are driving shifts, prompting companies to invest in new therapies.